ALENDRONATE FOR GLUCOCORTICOID-ASSOCIATED OSTEOPENIA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项试验将检验这样一个假设，即在患有克罗恩病、溃疡性结肠炎、全身性幼年类风湿性关节炎和幼年皮肌炎的儿童和青少年中，使用18个月的阿仑膦酸盐(Fosamax，Merck&Co.，Inc.)治疗糖皮质激素相关性骨量减少和骨质疏松。与18个月的标准护理治疗相比，双能X射线骨密度仪(DXA)测定的个人AP脊柱骨密度(Gm/cm)的平均变化将导致更大的改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This trial will test the hypothesis that among children and adolescents with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis and juvenile dermatomyositis, treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX, Merck & Co., Inc.) will result in greater improvement in mean changes in individual AP spine BMD (gm/cm) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard care therapy.